Search Results
Dec 17, 2025, 11:30 ET New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations
Both monthly maintenance doses (100 mg and 300 mg) improved opioid abstinence and were well-tolerated with no new safety signals identified.Post-hoc analyses indicated the 300-mg monthly maintenance dose performed significantly better than the 100-mg monthly dose in participants reporting
More news about: Indivior PLC
Dec 17, 2025, 06:45 ET PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
evaluation. Closely monitor blood glucose levels in patients with, or at risk for, diabetes mellitus or hyperglycemia. If blood glucose is elevated (>250 mg/dL), withhold PADCEV.Pneumonitis/Interstitial lung disease (ILD) Severe, life-threatening or fatal pneumonitis/ILD occurred in patients treated
More news about: Astellas Pharma Inc.
Dec 16, 2025, 12:00 ET From Social Shares to Equity Shares: Social Media Titan Alix Earle Invests in the Next Billion Dollar Beverage, GORGIE Energy
along with other strategic partners, GORGIE is a community-led wellness brand redefining energy with beauty and functional benefits. Each can delivers 150mg of clean green tea caffeine with added ingredients like Biotin, B Vitamins and L-Theanine - without aspartame, sucralose or erythritol. GORGIE is available
More news about: GORGIE
Dec 16, 2025, 07:30 ET REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata
https://doi.org/10.1111/ddg.14689National Alopecia Areata FoundationAlhanshali L, Buontempo MG, Lo Sicco KI, Shapiro J. Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs. Clin Cosmet Investig Dermatol. 2023;16:803-820
More news about: Nektar Therapeutics
Dec 16, 2025, 05:59 ET Breakthrough Progress: METiS TechBio Publishes Consecutive Research Findings in Nature Communications and the Journal for ImmunoTherapy of Cancer
responses—with full tumor clearance—at doses as low as 0.15 μg. In contrast, the protein-based TCE control achieved only ~50% tumor growth inhibition even at 1 mg/kg (approximately 20 μg). Durable T Cell Memory: Cured mice remained tumor-free upon rechallenge, indicating long-term
More news about: METiS TechBio
Dec 15, 2025, 11:05 ET Historic First in Women's Sexual Health: FDA Grants Approval for Addyi® (flibanserin) in Postmenopausal Women
Pharmaceuticals today announced a monumental milestone for women's health: the U.S. Food and Drug Administration (FDA) has approved Addyi® (flibanserin 100 mg) for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in women <65 years. This long-awaited decision closes a gap in care for millions of
More news about: Sprout Pharmaceuticals
Dec 15, 2025, 09:05 ET LEGACY CANNABIS BRAND ANNOUNCES CALIFORNIA SALES PARTNERSHIP
difference."Effective immediately, Petalfast will distribute Smokiez' entire California catalog, including 100mg Distillate 10-packs of Fruit Chews, 10-packs of minor cannabinoid blend Fruit Chews, 100mg scored bars, and all natural live resin SKUs."Petalfast is just as eager to join forces with a legacy
More news about: Smokiez Edibles
Dec 15, 2025, 08:37 ET Morphy's Dec. 16-18 Firearms & Militaria Auction Is a Virtual Arsenal of Premier Sporting Guns, Rare NFA and Other Prized Military Weapons
& 28-gauge side-by-side shotguns, Pedretti-engraved Purdey over-under ejector game gun, German Heckler & Koch MP5SD3 and Rheinmetal MG42/59 machine guns DENVER, Pa., Dec. 15, 2025 /PRNewswire/ -- Morphy's
More news about: Morphy Auctions
Dec 15, 2025, 08:00 ET Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium
justifies dose escalation and combination strategies to further improve patient outcomesKey takeawaysThe daily 10 mg (Z)-endoxifen dose was well tolerated, with 95% of patients completing ≥75% of therapy and low-grade side effects, demonstrating strong feasibility in
More news about: Atossa Therapeutics Inc
Dec 15, 2025, 07:00 ET Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
intravenous infusion of 750 mg imsidolimab, 300 mg imsidolimab, or placebo on Day 0. At Week 4 (primary endpoint), 53% of patients receiving either dose of imsidolimab achieved a GPPGA score of 0/1 (clear or almost clear skin), compared to 13% on placebo (p=0.0131 for 750 mg dose).Responders from
More news about: Vanda Pharmaceuticals Inc.
Dec 15, 2025, 07:00 ET RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
and several other viruses, such as Influenza A and Ebola. Opaganib delivered a statistically significant increase in survival time when given at 150 mg/kg twice a day (BID) in a United States Army Medical Research Institute of Infectious Diseases (USAMRIID) in vivo Ebola virus study, making it
More news about: RedHill Biopharma Ltd.
Dec 15, 2025, 05:00 ET Minghui Pharmaceutical Announces FDA clearance of IND to Initiate Global Phase Ⅲ Trials of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody, in Thyroid Eye Disease
emerging as a potential best-in-class therapy, supported by compelling Phase Ⅱ data:Active TED: At the 450 mg dose (n=32), MHB018A achieved an 81% proptosis response rate at Week 12, demonstrating stronger efficacy than reported for intravenous IGF-1R antibodies.
More news about: Minghui Pharmaceutical
Dec 15, 2025, 04:00 ET Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor
- The elimination half-life of ASC50 after a single oral dose was 43, 89, 91, 87, 104, and 85 hours for 10 mg, 30 mg, 100 mg, 200 mg, 400 mg, and 600 mg, respectively, supporting once-daily or potentially once-weekly oral dosing.- ASC50 had strong target engagement
More news about: Ascletis Pharma Inc.
Dec 15, 2025, 02:00 ET DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT
medication known as an angiotensin II receptor blocker (ARB). Once the ARB dose is stable, patients are then randomised to receive either DMX-200 (120 mg capsule, twice daily) or placebo for a 2-year treatment period. The single Phase 3 trial in FSGS patients is designed to capture evidence of proteinuria
More news about: Dimerix
Dec 12, 2025, 20:25 ET U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
prednisone 5 mg daily in combination with AKEEGA®, Grades 3-4 hypokalemia was detected in 9% of patients on the AKEEGA® arm, and Grades 3-4 hypertension was observed in 30% of patients on the AKEEGA® arm.In MAGNITUDE Cohort 1, which used prednisone 10 mg daily in combination
More news about: Johnson & Johnson
Dec 12, 2025, 13:23 ET Efeitos imediatos: descobrimos os tratamentos que vão recuperar o glow da sua pele a tempo de aproveitar as festas de final de ano
suavizar olheiras, linhas de expressão e rugas, sem afetar a naturalidade dos traços individuais do paciente", explica o dermatologista Marcus Morais (CRM-MG 38194/ RQE 16968).Entre as opções que ajudam a recuperar o brilho da pele,
More news about: Galderma
Dec 12, 2025, 11:45 ET Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
of 200 mg twice daily or 150 mg twice daily, reduce the Verzenio dose to 100 mg twice daily with concomitant use of strong CYP3A inhibitors other than ketoconazole. In patients who have had a dose reduction to 100 mg twice daily due to adverse reactions, further reduce the Verzenio dose to 50 mg twice
More news about: Eli Lilly and Company
Dec 12, 2025, 10:47 ET Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
anticipated study start in 2026."Tango reported that vopimetostat demonstrated a potentially best-in-class safety and tolerability profile at 250 mg once daily with no drug-related dose discontinuations and an 8% dose reduction rate, while combination studies with Revolution Medicines' RAS(ON)
More news about: USA News Group
Dec 12, 2025, 09:18 ET AusperBio Announces AHB-137 Monotherapy Achieved 30% Functional Cure Rate in HBe-negative CHB Patients on Stable Nucleos(t)ide Analogue (NA) Therapy
functional cure (HBsAg <0.05 IU/mL and HBV DNA<LLOQ) in both 225 mg and 300 mg cohorts. In patients with baseline HBsAg 100–3,000 IU/mL, functional cure was achieved in 13% (225 mg) and 19% (300 mg). Based on these results, the 300 mg dose has been selected for further Phase II studies.Highly
More news about: AusperBio Therapeutics Inc.
Dec 12, 2025, 05:33 ET Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion
authorization for the product that was developed by Bio-Thera under the code BAT2506. Following approval, the monoclonal antibody would be supplied as 50mg/0.5mL and 100mg/mL in a pre-filled syringe. The marketing authorization would apply across the 27 member states of the European Union, in addition to Norway,
More news about: Bio-Thera Solutions, Ltd
Dec 11, 2025, 19:00 ET Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity
After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectively, with corresponding body weight reductions of 7.72 kg and 8.65 kg. These results were significantly superior to those observed in the
More news about: Innovent Biologics
Dec 11, 2025, 18:09 ET FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
Patients on steroids at baseline began tapering at Week 4 to reach prednisone 5 mg per day by Week 24. By Week 26, 87.4% of patients taking UPLIZNA and 84.6% of those taking placebo had reduced their steroid dose to 5 mg or less per day.6 "UPLIZNA showed strong efficacy at 26 weeks
More news about: Amgen
Dec 11, 2025, 17:31 ET Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight
pomalidomide-refractory and had previously failed on BCMA and/or T-cell engager therapy, inobrodib achieved objective response rates of 60% at 20 mg and 75% at 30 mg—representing at least a two-fold increase compared to real-world response rates of 25-30% in similar patient populations after BCMA/bispecific
More news about: DelveInsight Business Research, LLP
Dec 11, 2025, 12:30 ET Your Secret Weapon for Holiday Party Season: Potatoes
Eggnog Donut Holes, and more for an iconic holiday movie marathonPlus, potatoes have more potassium than a banana (620 mg vs 450 mg) and deliver 30% of your daily vitamin C, so you can fuel up while you party down.No matter what or where you're celebrating, there's a spud
More news about: Potatoes USA
Dec 11, 2025, 08:30 ET CENTURY LITHIUM HIGHLIGHTS RARE EARTH POTENTIAL AT ANGEL ISLAND, NEVADA
light rare earth elements and 25% yttrium and heavy rare earth elements. Chloride leaching of the sample yielded solution concentrations of 210 mg/l lithium and 36 mg/l TREO, indicating that the REEs enter solution under the same conditions as used for lithium extraction.Two ion-exchange ("IX") media
More news about: Century Lithium Corp.